197 related articles for article (PubMed ID: 23314908)
1. Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines.
Kokatla HP; Yoo E; Salunke DB; Sil D; Ng CF; Balakrishna R; Malladi SS; Fox LM; David SA
Org Biomol Chem; 2013 Feb; 11(7):1179-98. PubMed ID: 23314908
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues.
Shukla NM; Malladi SS; Mutz CA; Balakrishna R; David SA
J Med Chem; 2010 Jun; 53(11):4450-65. PubMed ID: 20481492
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of novel human Toll-like receptor 8 agonists.
Kokatla HP; Sil D; Tanji H; Ohto U; Malladi SS; Fox LM; Shimizu T; David SA
ChemMedChem; 2014 Apr; 9(4):719-23. PubMed ID: 24474703
[TBL] [Abstract][Full Text] [Related]
4. Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.
Kokatla HP; Sil D; Malladi SS; Balakrishna R; Hermanson AR; Fox LM; Wang X; Dixit A; David SA
J Med Chem; 2013 Sep; 56(17):6871-85. PubMed ID: 23899291
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.
Shukla NM; Mutz CA; Malladi SS; Warshakoon HJ; Balakrishna R; David SA
J Med Chem; 2012 Feb; 55(3):1106-16. PubMed ID: 22239408
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
[TBL] [Abstract][Full Text] [Related]
7. The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.
Dowling DJ; Tan Z; Prokopowicz ZM; Palmer CD; Matthews MA; Dietsch GN; Hershberg RM; Levy O
PLoS One; 2013; 8(3):e58164. PubMed ID: 23483986
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs.
Yang M; Larson PG; Brown L; Schultz JR; Kucaba TA; Griffith TS; Ferguson DM
Bioorg Med Chem Lett; 2022 Mar; 59():128548. PubMed ID: 35051578
[TBL] [Abstract][Full Text] [Related]
9. Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines.
Beesu M; Malladi SS; Fox LM; Jones CD; Dixit A; David SA
J Med Chem; 2014 Sep; 57(17):7325-41. PubMed ID: 25102141
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.
Smith AJ; Li Y; Bazin HG; St-Jean JR; Larocque D; Evans JT; Baldridge JR
Vaccine; 2016 Aug; 34(36):4304-12. PubMed ID: 27402566
[TBL] [Abstract][Full Text] [Related]
11. The Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production by Human Newborn and Adult Leukocytes.
Ganapathi L; Van Haren S; Dowling DJ; Bergelson I; Shukla NM; Malladi SS; Balakrishna R; Tanji H; Ohto U; Shimizu T; David SA; Levy O
PLoS One; 2015; 10(8):e0134640. PubMed ID: 26274907
[TBL] [Abstract][Full Text] [Related]
12. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways.
Philbin VJ; Dowling DJ; Gallington LC; Cortés G; Tan Z; Suter EE; Chi KW; Shuckett A; Stoler-Barak L; Tomai M; Miller RL; Mansfield K; Levy O
J Allergy Clin Immunol; 2012 Jul; 130(1):195-204.e9. PubMed ID: 22521247
[TBL] [Abstract][Full Text] [Related]
13. Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
Hunt JR; Kleindl PA; Moulder KR; Prisinzano TE; Forrest ML
Bioorg Med Chem Lett; 2020 Jan; 30(2):126788. PubMed ID: 31784317
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity.
Beesu M; Caruso G; Salyer AC; Khetani KK; Sil D; Weerasinghe M; Tanji H; Ohto U; Shimizu T; David SA
J Med Chem; 2015 Oct; 58(19):7833-49. PubMed ID: 26351878
[TBL] [Abstract][Full Text] [Related]
15. TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity.
Du J; Wu Z; Ren S; Wei Y; Gao M; Randolph GJ; Qu C
Vaccine; 2010 Aug; 28(38):6273-81. PubMed ID: 20637759
[TBL] [Abstract][Full Text] [Related]
16. Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds.
Dolšak A; Švajger U; Lešnik S; Konc J; Gobec S; Sova M
Eur J Med Chem; 2019 Oct; 179():109-122. PubMed ID: 31247373
[TBL] [Abstract][Full Text] [Related]
17. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands.
Tanji H; Ohto U; Shibata T; Miyake K; Shimizu T
Science; 2013 Mar; 339(6126):1426-9. PubMed ID: 23520111
[TBL] [Abstract][Full Text] [Related]
18. Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
Beesu M; Salyer AC; Brush MJ; Trautman KL; Hill JK; David SA
J Med Chem; 2017 Mar; 60(5):2084-2098. PubMed ID: 28146629
[TBL] [Abstract][Full Text] [Related]
19. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
[TBL] [Abstract][Full Text] [Related]
20. Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
Bazin HG; Bess LS; Livesay MT; Li Y; Cybulski V; Miller SM; Johnson DA; Evans JT
Bioorg Med Chem Lett; 2020 Mar; 30(6):126984. PubMed ID: 32001135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
